MULTIPLE MYELOMA

Latest News

Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma

July 18th 2024

During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.

Cilta-cel is Safe, Feasible in Outpatient Settings for R/R Multiple Myeloma
Cilta-cel is Safe, Feasible in Outpatient Settings for R/R Multiple Myeloma

July 16th 2024

Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma
Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma

July 15th 2024

 Deep and Durable Responses: Ide-Cel CAR T Shows Promise for High-Risk Multiple Myeloma Relapse
Deep and Durable Responses: Ide-Cel CAR T Shows Promise for High-Risk Multiple Myeloma Relapse

July 4th 2024

New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival
New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival

July 2nd 2024

More News